Early Post-RP Complications Directly Related to Age
The risk of virtually all early postoperative complications increases with increasing patient age at radical prostatectomy for localized prostate cancer.
PROSTATE CANCER ADVISOR
Prostate Cancer
Features
-
-
PCa Phenotype May Predict Response to Immune Checkpoint Blockade
The MSI-H/dMMR phenotype in men with advanced PCa is associated with greater likelihood of a durable response to PD-1/PD-L1 inhibitors. -
Prostate Cancer Detection Improved With Combined Biopsy Targeting
In a study, visual registration in conjunction with image fusion resulted in the highest detection rate of clinically significant prostate cancer. -
Delayed Prostate Cancer Treatment May Up Relapse Risk
Patients whose radical prostatectomy was delayed more than 6 months had a nearly 2-fold increased risk of biochemical recurrence, a study found.
Latest Prostate Cancer News
High Gleason Pattern at PSM Ups Prostate Cancer Relapse Risk
Gleason pattern 4 or 5 found at a positive surgical margin following robot-assisted radical prostatectomy predicts early biochemical recurrence.
Prostate Cancer Mortality Lowest With Radical Prostatectomy
In a study with a follow-up period of 18 years, men treated with any other modality but radical prostatectomy had higher prostate cancer death risks.
TRT Speeds Potency Recovery After Prostate Surgery
In a study, all men who received testosterone replacement therapy within 1 year of robot-assisted radical prostatectomy had full potency recovery at 24 months.
TRT Reduces Post-RARP Recurrence Risk in Low-Risk Prostate Cancer
Testosterone replacement therapy prolonged time to disease progression among men who underwent radical surgery for localized prostate cancer.
Intense ADT Prior to RP May Improve Outcomes in Locally Advanced PCa
A phase 2 study demonstrated higher rates of pathologic complete response or minimal residual disease.
Long-Term Use of Low-Dose Aspirin May Lower PCa Mortality
A population-based study found no effect of low-dose aspirin use within 1 year of diagnosis on prostate cancer death risk.
Time from Definitive Therapy to ADT Predicts mCRPC Risk
Time from definitive therapy for localized prostate cancer to the start of androgen deprivation therapy (ADT) independently predicts the risk of metastatic castration-resistant prostate cancer (mCRPC) and death, a new study suggests. The study, led by Neeraj Agarwal, MD, of the Huntsman Cancer Institute at the University of Utah in Salt Lake City, included 253…
Prostate Cancer Risk After Single Negative Biopsy Quantified
Almost one quarter of men who have a single negative prostate biopsy are eventually diagnosed with prostate cancer (PCa) within 20 years, according to investigators. The finding is from a study of 95,675 men who had a negative first transrectal ultrasound (TRUS)-guided prostate biopsy from January 1994 to October 2014. The 5-, 10-, 15, and…
Online Calculator May Aid In Individualizing Prostate Cancer Care
Researchers at the University of Michigan in Ann Arbor have proposed an online calculator to aid patients with localized prostate cancer (PCa) in deciding whether surgery or radiation therapy is their best treatment option, a question that randomized trials have not fully addressed. “Helping guide men with localized prostate cancer through their initial treatment decision…
First-Year Post-ADT Weight Loss Predicts Higher PCa Death Risk
Weight loss in the first year after starting androgen deprivation therapy in men who have undergone radical surgery for prostate cancer ups the risk of metastatic disease and death from prostate cancer.
Want to read more?
Please login or register first to view this content.
Next post in Prostate Cancer
